Phase I study of 4'-deoxydoxorubicin (esorubicin) in children with malignant solid tumors.

Abstract

4'-Deoxydoxorubicin was given to 15 patients with drug-resistant pediatric malignant solid tumors with the objectives of determining the maximum tolerated dosage and dose-limiting toxicity. Maximum tolerated dosage was 36 mg/m2 given IV once every 3 weeks. Dose limiting toxicity was myelosuppression, which was severe and prolonged. Therapeutic benefits were not observed for these patients.

• Authors: C B Pratt, E C Douglass, W H Meyer, F A Hayes, M E Horowitz, E I Thompson, L Avery
• Journal: Investigational new drugs (Invest New Drugs) Vol. 7 Issue 2-3 Pg. 209-11 (Jul 1989) ISSN: 0167-6997 [Print] United States
• PMID: 2793374 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antineoplastic Agents
• Doxorubicin
• esorubicin

Topics

• Adolescent
• Adult
• Antineoplastic Agents (administration & dosage, adverse effects, therapeutic use)
• Child
• Child, Preschool
• Doxorubicin (administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
• Drug Evaluation
• Female
• Hematologic Diseases (chemically induced)
• Humans
• Male
• Neoplasms (drug therapy)